4-哌嗪-1-基-呋喃并吡啶 | 81078-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-哌嗪-1-基-呋喃并吡啶
• 英文名称: 4-(1-piperazinyl)furo<3,2-c>pyridine
• 英文别名: 4-piperazin-1-ylfuro[3,2-c]pyridine；4-piperazine-1-yl-furo[3,2-c]pyridine；4-(1-Piperazinyl)furo[3,2-c]pyridine；4-piperazin-1-yl-furo[3,2-c]pyridine；4-(Piperazin-1-yl)furo[3,2-c]pyridine
• CAS: 81078-84-4
• 化学式: C₁₁H₁₃N₃O
• 分子量: 203.244
• InChiKey: LUIZVTKJWSGSPA-UHFFFAOYSA-N

物化性质

• 熔点：
  58 °C
• 沸点：
  378.8±32.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

SDS

Name:	4-Piperazin-1-yl-furo[3 2-c]pyridine Material Safety Data Sheet
Synonym:	None Known
CAS:	81078-84-4

Section 1 - Chemical Product MSDS Name:4-Piperazin-1-yl-furo[3 2-c]pyridine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
81078-84-4	4-Piperazin-1-yl-furo[3,2-c]pyridine	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 22 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Harmful if swallowed. Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 81078-84-4: Personal Protective Equipment Eyes: Wear chemical splash goggles and face shield.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: Pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H13N3O
Molecular Weight: 203.25

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 81078-84-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Piperazin-1-yl-furo[3,2-c]pyridine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2922
Packing Group: II
IMO
Shipping Name: CORROSIVE LIQUID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2922
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE LIQUID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2922
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 22 Harmful if swallowed.
R 34 Causes burns.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 81078-84-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 81078-84-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 81078-84-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-哌嗪-1-基-呋喃并吡啶 在 5%-palladium/activated carbon 盐酸 、 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 71.5h， 生成 trans-N-(4-{2-[4-(2,3-Dihydro-furo[3,2-c]pyridin-4-yl)-piperazin-1-yl]-ethyl}-cyclo hexyl)-acetamide
  参考文献：
  名称：

  [EN] ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS
  [FR] COMPOSÉS PYRIDINIQUES ANNELÉS COMME MODULATEURS DUAUX DES RÉCEPTEURS 5-HT2A ET D3

  摘要：

  本发明涉及公式（I）中的新型5-HT2A和D3受体的双调节剂，其中X、Y、A、R1、R2和R3如本文所述，以及其药学上可接受的盐和酯。此外，本发明涉及制备公式（I）化合物，包括它们的药物组合物以及它们作为药物的用途。

  公开号：

  WO2011161009A1
• 作为产物：
  描述：

  4,5-二氢-4-氧代呋喃[3,2]吡啶 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 4-哌嗪-1-基-呋喃并吡啶
  参考文献：
  名称：

  噻吩并[3,2-c]吡啶和呋喃并[3,2-c]吡啶环：具有潜在抗精神病活性的新药效基团。

  摘要：

  已经合成了两种新的芳基哌嗪衍生物，即4-（1-哌嗪基）噻吩并-和呋喃并[3,2-c]吡啶环系统，并通过四亚甲基链连接到各种酰亚胺环上。发现来自每个系列的目标化合物在阿朴吗啡定型和阿朴吗啡诱导的爬升，Sidman回避反应和条件回避反应中具有显着活性。另外，尽管对于硫代和呋喃并[3，2-c]吡啶衍生物均观察到对5-羟色胺5-HT1和5-HT2受体的强亲和力，但这些分子与多巴胺D2受体的相互作用较弱。每个系列涉及化合物22和33的先导原型的电生理研究表明，这两个分子对A9和A10区域的多巴胺神经元有明显不同的作用。

  DOI：

  10.1021/jm00126a002

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• Design and Synthesis of Piperazinylpyridine Derivatives as Novel 5-HT1A Agonists/5-HT3 Antagonists for the Treatment of Irritable Bowel Syndrome (IBS)
  作者：Akira Asagarasu、Teruaki Matsui、Hiroyuki Hayashi、Satoru Tamaoki、Yukinao Yamauchi、Michitaka Sato

  DOI：10.1248/cpb.57.34

  日期：——

  We have prepared a series of piperazinylpyridine derivatives for the treatment of irritable bowel syndrome (IBS). These compounds, which were designed by pharmacophore analysis, bind to both serotonin subtype 1A (5-HT1A) and subtype 3 (5-HT3) receptors. The nitrogen atom of the isoquinoline, a methoxy group and piperazine were essential to the pharmacophore for binding to these receptors. We also synthesized furo- and thienopyridine derivatives according to structure–activity relationship analyses. Compound 17c (TZB-20810) had high affinities to these receptors and exhibited 5-HT1A agonistic activity and 5-HT3 antagonistic activity concurrently, and is a promising drug for further development in the treatment of IBS.

  我们已准备了一系列哌嗪吡啶衍生物用于治疗肠易激综合征（IBS）。这些化合物通过药效团分析设计，能够同时与血清素亚型1A（5-HT1A）和亚型3（5-HT3）受体结合。异喹啉的氮原子、一个甲氧基和哌嗪是与这些受体结合的药效团的重要组成部分。我们还根据结构-活性关系分析合成了呋喃和噻吡啶衍生物。化合物17c（TZB-20810）对这些受体具有很高的亲和力，同时展现出5-HT1A激动剂活性和5-HT3拮抗剂活性，是治疗IBS方面具有进一步开发潜力的有前景药物。
• Pyridine compounds
  申请人：Les Laboratoires Servier

  公开号：US06399616B1

  公开（公告）日：2002-06-04

  A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, n represents an integer from 2 to 3 inclusive, Z represents a single bond, A represents nitrogen, Q represents nitrogen, M, together with the carbon of pyridyl to which it is bonded, represents thieno, furo, pyrrolo or oxopyrrolo, Its optical isomers and pharmaceutically-acceptable acid or base additional salts thereof, and Medicinal products containing the same which are useful in the treatment of CNS disorders. It being understood that “aryl” is phenyl, naphthyl, dihydronaphthyl, or tetrahydronaphthyl.

  从以下式(I)中选择的化合物：其中：W代表可选择取代的萘基，n代表一个从2到3的整数，Z代表一个单键，A代表氮，Q代表氮，M与其结合的吡啶基的碳一起代表噻吩、呋喃、吡咯或氧代吡咯，其光学异构体和药学上可接受的酸或碱盐，以及含有这些化合物的药用产品，适用于治疗中枢神经系统疾病。理解“芳基”是苯基、萘基、二氢萘基或四氢萘基。
• Antipsychotic fused-ring pyridinylpiperazine derivatives
  申请人：Bristol-Myers Company

  公开号：US04677104A1

  公开（公告）日：1987-06-30

  Disubstituted 1,4-piperazinyl derivatives are disclosed wherein one substituent is a bicyclic fused-ring furo-, pyrrolo-, cyclopentadieno-, or thieno-pyridine heterocyclic system and the second substituent is an alkylene chain attached to cyclic imide heterocycles, such as azaspiro[4.5]decanediones, dialkylglutarimides, thiazolidinediones, succinimides, and morpholine-2,6-diones; or a benzylic carbinol moiety. These compounds have potent antipsychotic and serotonin antagonist activities. 4-[4-[4-(4-Furo[3,2-c]pyridinyl)-1-piperazinyl]butyl]-3,5-morpholinedione is an example of a typical embodiment having selective antipsychotic activity.

  披露了二取代的1,4-哌嗪衍生物，其中一个取代基是一个融合环的呋喃、吡咯、环戊二烯或噻吩-吡啶杂环系统，第二个取代基是连接到环状咪唑环的烷基链，例如氮杂螺[4.5]癸烷二酮，二烷基戊二酰亚胺，噻唑烷二酮，琥珀酰亚胺和吗啉-2,6-二酮；或苄基醇基团。这些化合物具有强效的抗精神病和5-羟色胺拮抗活性。4-[4-[4-(4-呋喃[3,2-c]吡啶基)-1-哌嗪基]丁基]-3,5-吗啉二酮是一个具有选择性抗精神病活性的典型实施例。
• ANELLATED PYRIDINE COMPOUNDS
  申请人：Gobbi Luca

  公开号：US20110313151A1

  公开（公告）日：2011-12-22

  The present invention is concerned with novel dual modulators of the 5-HT 2A and D 3 receptors of formula (I) wherein X, Y, A, R 1 , R 2 , and R 3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as therapeutics.

  本发明涉及一种新颖的双调节剂，用于5-HT2A和D3受体，其化学式为(I)，其中X、Y、A、R1、R2和R3如本文所述，以及其药学上可接受的盐和酯。此外，本发明涉及制备化合物(I)、包含它们的药物组合物以及它们作为治疗药物的用途。